SureFection Technology for High-Throughput Primary Cell Transfection

Information

  • Research Project
  • 7665098
  • ApplicationId
    7665098
  • Core Project Number
    R44RR022955
  • Full Project Number
    5R44RR022955-03
  • Serial Number
    22955
  • FOA Number
    PA-07-280
  • Sub Project Id
  • Project Start Date
    5/1/2006 - 18 years ago
  • Project End Date
    11/30/2010 - 14 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    8/1/2009 - 15 years ago
  • Budget End Date
    11/30/2010 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/27/2009 - 15 years ago

SureFection Technology for High-Throughput Primary Cell Transfection

DESCRIPTION (provided by applicant): Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer, cardiovascular and inflammatory diseases. Unfortunately, utility of precious primary cells is largely hindered by lack of effective means for transfection with minimal side effects, particularly in high-throughput mode. Our proposal is specifically designed to address this critical unmet need. Our Phase I studies have demonstrated that our technology is superior than existing methods in transfecting primary cells, especially fully differentiated primary cell monolayers. Phase II work is proposed to develop a 96-well high-throughput transfection system, and to further validate its applicability in extended primary cultures, including both adherent and suspension cells. Success in this project would have notable impact on basic research and therapeutic development by expanding the utility of primary cells, which are the best in vitro models to human. Success in this project will benefit public health by advancing basic research in decoding the functional roles of ~25,000 human genes, and by impacting therapeutic development for fighting diseases like cancer and inflammation.

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R44
  • Administering IC
    RR
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    654082
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    389
  • Ed Inst. Type
  • Funding ICs
    NCRR:654082\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    RATIONAL BIOTECHNOLOGY, INC.
  • Organization Department
  • Organization DUNS
    615333593
  • Organization City
    Menlo Park
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94025
  • Organization District
    UNITED STATES